[go: up one dir, main page]

CN106132956A - 一类杂环化合物、其制备方法和用途 - Google Patents

一类杂环化合物、其制备方法和用途 Download PDF

Info

Publication number
CN106132956A
CN106132956A CN201580008897.5A CN201580008897A CN106132956A CN 106132956 A CN106132956 A CN 106132956A CN 201580008897 A CN201580008897 A CN 201580008897A CN 106132956 A CN106132956 A CN 106132956A
Authority
CN
China
Prior art keywords
piperazin
alkyl
group
ethyl
benzothien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580008897.5A
Other languages
English (en)
Other versions
CN106132956B (zh
Inventor
蒋华良
王震
李剑峰
张容霞
何洋
柳永建
毕明浩
刘正
田广辉
陈伟铭
杨飞瀑
吴春晖
王瑜
蒋翔锐
尹敬敬
王贯
沈敬山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Wangshan Wangshui Biopharmaceutical Co ltd
Shanghai Institute of Materia Medica of CAS
Topharman Shandong Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Topharman Shandong Co Ltd
Suzhou Vigonvita Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Topharman Shandong Co Ltd, Suzhou Vigonvita Life Sciences Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN106132956A publication Critical patent/CN106132956A/zh
Application granted granted Critical
Publication of CN106132956B publication Critical patent/CN106132956B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明提供了一种由通式(I)表示的杂环化合物、其立体异构体或其药学上可接受的盐、其药物组合物、以及其在制备预防和/或治疗中枢神经系统疾病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN201580008897.5A 2014-03-07 2015-03-09 一类杂环化合物、其制备方法和用途 Active CN106132956B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014100836028 2014-03-07
CN201410083602 2014-03-07
CN2014108539509 2014-12-31
CN201410853950.9A CN104892589A (zh) 2014-03-07 2014-12-31 一类杂环化合物、其制备方法和用途
PCT/CN2015/073854 WO2015131856A1 (zh) 2014-03-07 2015-03-09 一类杂环化合物、其制备方法和用途

Publications (2)

Publication Number Publication Date
CN106132956A true CN106132956A (zh) 2016-11-16
CN106132956B CN106132956B (zh) 2019-12-10

Family

ID=54025602

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201410853950.9A Pending CN104892589A (zh) 2014-03-07 2014-12-31 一类杂环化合物、其制备方法和用途
CN201580008897.5A Active CN106132956B (zh) 2014-03-07 2015-03-09 一类杂环化合物、其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410853950.9A Pending CN104892589A (zh) 2014-03-07 2014-12-31 一类杂环化合物、其制备方法和用途

Country Status (9)

Country Link
US (1) US10174011B2 (zh)
EP (1) EP3115361B1 (zh)
JP (1) JP6395850B2 (zh)
KR (1) KR101840249B1 (zh)
CN (2) CN104892589A (zh)
AU (1) AU2015226578B2 (zh)
CA (1) CA2941771C (zh)
RU (1) RU2667498C2 (zh)
WO (1) WO2015131856A1 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104557896A (zh) * 2013-10-18 2015-04-29 沈敬山 布瑞哌唑、其关键中间体及其盐的制备方法
JP2018502158A (ja) * 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ，インコーポレイティド パーキンソン病と関連する精神病の治療方法
JP2018502157A (ja) * 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ，インコーポレイティド アルツハイマー病の治療方法
EP3244896B1 (en) * 2015-01-12 2024-06-12 Reviva Pharmaceuticals, Inc. Methods for treating pulmonary hypertension
EP3150591A1 (en) * 2015-10-02 2017-04-05 Crystal Pharma S.A.U Process and intermediates for the preparation of benzo[b]thiophene compounds
CN105461608B (zh) * 2015-11-23 2017-11-28 东南大学 二氢吲哚‑2‑酮类d3受体配体及其制备方法和用途
US10464931B2 (en) 2015-12-28 2019-11-05 Honour (R&D) Process for the preparation of Quinolin-2(1H)-one derivatives
CN106478548A (zh) * 2016-07-19 2017-03-08 贵州大学 一种6‑羟基灭草松的制备工艺
CN107098855A (zh) * 2017-04-05 2017-08-29 上海诺星医药科技有限公司 一种制备7‑羟基‑2‑喹啉酮的方法
WO2019242717A1 (zh) * 2018-06-21 2019-12-26 中国科学院上海药物研究所 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
CN111004211B (zh) * 2019-12-29 2021-04-02 苏州诚和医药化学有限公司 一种依匹哌唑中间体4-溴苯并［b］噻吩的合成方法
US20240208969A1 (en) * 2021-04-12 2024-06-27 Impact Therapeutics (Shanghai), Inc. Substituted fused bicyclic compounds as parp inhibitors and the use thereof
EP4382521A4 (en) * 2021-08-05 2025-01-01 Shujing Biopharma Co Ltd REGULATOR CONTAINING A TRICYCLIC DERIVATIVE, ITS PREPARATION PROCESS AND ITS USE
CN116425716A (zh) * 2021-12-31 2023-07-14 南京艾德凯腾生物医药有限责任公司 一种依匹哌唑中间体的制备方法
US11851435B2 (en) * 2022-03-07 2023-12-26 National Health Research Institutes PTGR2 inhibitors and their use
EP4493551A1 (en) 2022-03-14 2025-01-22 Slap Pharmaceuticals LLC Multicyclic compounds
CN116891465A (zh) 2022-03-30 2023-10-17 苏州旺山旺水生物医药有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137894A (en) * 1991-12-05 1992-08-11 New James S 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
WO2002050067A2 (en) * 2000-12-20 2002-06-27 Eli Lilly And Company Pharmaceutical heterocyclic compounds
WO2004046124A1 (en) * 2002-11-21 2004-06-03 Glaxo Group Limited Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
CN101155804A (zh) * 2005-04-14 2008-04-02 大塚制药株式会社 用于治疗精神疾病的哌嗪取代的苯并噻吩
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
WO2009094279A1 (en) * 2008-01-25 2009-07-30 Merck & Co., Inc. Quinolizidinone m1 receptor positive allosteric modulators
US20100063047A1 (en) * 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
CN101754964A (zh) * 2007-07-19 2010-06-23 库多斯药物有限公司 Dna pk抑制剂
WO2011111875A1 (en) * 2010-03-11 2011-09-15 Dainippon Sumitomo Pharma Co., Ltd. N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
WO2013024291A2 (en) * 2011-08-18 2013-02-21 Ucb Pharma S.A. Therapeutically active fused pyrimidine derivatives
CN102984941A (zh) * 2009-09-04 2013-03-20 密执安大学评议会 用于治疗白血病的组合物和方法
JP2014162781A (ja) * 2013-02-27 2014-09-08 Otsuka Pharmaceut Co Ltd 複素環化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5824680A (en) 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
UA84566C2 (ru) * 2004-06-09 2008-11-10 Солвей Фармасьютикалс Б.В. Производные тиофенпиримидинонов и их применение в терапии, фармацевтическая композиция на их основе
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
JP2008037850A (ja) 2006-08-10 2008-02-21 Mitsubishi Tanabe Pharma Corp 新規置換ピペリジン誘導体
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2008115175A (ja) 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd 複素環化合物
WO2010103130A2 (en) * 2009-03-13 2010-09-16 Katholieke Universiteit Leuven, K.U.Leuven R&D Novel bicyclic heterocycles
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2016003296A1 (en) * 2014-07-04 2016-01-07 Instytut Farmakologii Polskiej Akademii Nauk (quinoline or isoquinoline)sulfonamides of cyclic amines as antipsychotic drugs

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137894A (en) * 1991-12-05 1992-08-11 New James S 4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
WO2002050067A2 (en) * 2000-12-20 2002-06-27 Eli Lilly And Company Pharmaceutical heterocyclic compounds
WO2004046124A1 (en) * 2002-11-21 2004-06-03 Glaxo Group Limited Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
CN101155804A (zh) * 2005-04-14 2008-04-02 大塚制药株式会社 用于治疗精神疾病的哌嗪取代的苯并噻吩
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
CN101754964A (zh) * 2007-07-19 2010-06-23 库多斯药物有限公司 Dna pk抑制剂
WO2009094279A1 (en) * 2008-01-25 2009-07-30 Merck & Co., Inc. Quinolizidinone m1 receptor positive allosteric modulators
US20100063047A1 (en) * 2008-09-10 2010-03-11 Kalypsys, Inc. Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
CN102186479A (zh) * 2008-09-10 2011-09-14 凯利普西斯公司 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
CN102984941A (zh) * 2009-09-04 2013-03-20 密执安大学评议会 用于治疗白血病的组合物和方法
WO2011111875A1 (en) * 2010-03-11 2011-09-15 Dainippon Sumitomo Pharma Co., Ltd. N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
WO2013024291A2 (en) * 2011-08-18 2013-02-21 Ucb Pharma S.A. Therapeutically active fused pyrimidine derivatives
JP2014162781A (ja) * 2013-02-27 2014-09-08 Otsuka Pharmaceut Co Ltd 複素環化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COLUMBUS，OHIO，US: "DATABASE REGISTRY [Online]", 《STN检索报告》 *
JOLANTA GREMBECKA，等: ""Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia"", 《NATURE CHEMICAL BIOLOGY》 *

Also Published As

Publication number Publication date
EP3115361A1 (en) 2017-01-11
WO2015131856A1 (zh) 2015-09-11
AU2015226578A1 (en) 2016-10-20
RU2016137169A3 (zh) 2018-03-21
US20170158680A1 (en) 2017-06-08
CA2941771A1 (en) 2015-09-11
CA2941771C (en) 2020-02-18
KR20160122269A (ko) 2016-10-21
EP3115361B1 (en) 2019-10-23
JP2017508756A (ja) 2017-03-30
US10174011B2 (en) 2019-01-08
CN106132956B (zh) 2019-12-10
RU2667498C2 (ru) 2018-09-21
RU2016137169A (ru) 2018-03-21
JP6395850B2 (ja) 2018-09-26
EP3115361A4 (en) 2017-04-26
KR101840249B1 (ko) 2018-03-20
CN104892589A (zh) 2015-09-09
AU2015226578B2 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
CN106132956A (zh) 一类杂环化合物、其制备方法和用途
AU2005206571B8 (en) Compounds and methods of use
US10220030B2 (en) Amino-quinolines as kinase inhibitors
AU2010339423B2 (en) Therapeutic compounds and related methods of use
AU2012296411B2 (en) Amino quinazolines as kinase inhibitors
EP3752491A1 (en) Heterocyclic compounds as kinase inhibitors
JP2017513879A5 (zh)
JP2020514267A5 (zh)
JP2014511884A5 (zh)
JP2018505880A (ja) がんの治療のための化合物
CA2763099A1 (en) Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
JP2016500073A5 (zh)
US20140107100A1 (en) Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
HRP20160096T1 (hr) Supstituirani derivati izokinolina
JP2012506848A5 (zh)
CA2571627A1 (en) Substituted aryl-amine derivatives and methods of use
JP2017149734A (ja) 治療用化合物、及び関連する使用の方法
AU2022210517A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
JP2020510092A5 (zh)
JP2013520407A5 (zh)
EP2254889A1 (en) Protein kinase inhibitors and use thereof
JP2018514552A5 (zh)
JP2007522235A5 (zh)
JP2019537581A5 (zh)
RU2018124788A (ru) Замещенные бензазиноны в качестве антибактериальных соединений

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee after: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Country or region after: China

Patentee after: Suzhou Wangshan Wangshui Biopharmaceutical Co.,Ltd.

Patentee after: TOPHARMAN SHANDONG Co.,Ltd.

Address before: 201203 555 Zhangjiang Road, Zhangjiang, Pudong New Area, Shanghai

Patentee before: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Country or region before: China

Patentee before: SUZHOU VIGONVITA LIFE SCIENCES Co.,Ltd.

Patentee before: TOPHARMAN SHANDONG Co.,Ltd.